Unlocking the Potential of NOD2
A Powerful Target,
Out of Reach Until Now
Despite its therapeutic potential, development of NOD2-targeted therapies has been largely stymied by inflammatory side effects, leaving the field mostly undeveloped.
In animal models, NOD2 ligands have demonstrated activity across a remarkably broad range of diseases, including multiple viral infections, bacterial and fungal infections, osteosarcoma, inflammatory bowel disease, dermatitis, Type 2 diabetes, and Alzheimer's Disease.
Laurentide is developing LDPP, the first and only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. By avoiding the initial inflammatory side effects associated with other NOD2 ligands, LDPP has the potential to unlock the therapeutic value of this powerful but largely undrugged target.
NOVEL SCIENCE
A proprietary LDPP platform designed to selectively modulate NOD2 biology.
HOST-DIRECTED
Activating the body's own immune response rather than directly targeting pathogens.
BROAD POTENTIAL
A platform with potential applications across multiple disease areas.
ADVANCING A PLATFORM FOR MULTIPLE DISEASES
Laurentide is evaluating the potential of its platform across multiple therapeutic areas while advancing its viral disease program.
Viral Disease
Neuroinflammatory
Disease
Metabolic Syndrome
& Type II Diabetes
